Of the 57 patients included in this study, 9 (15.8%) had a tumor with MMRd, 2 (3.5%) had a tumor with POLE mutation, 45 (78.9%) tumors were p53wt, and 1 tumor (1.8%) had p53abn. This evidence concerns the gene POLE and neoplasm.